Suppliers are investing in production to support deals with AstraZeneca, Bayer and other drugmakers that are advancing radioisotope-based cancer therapies.

Original title: “Radiopharma Sector Races To Secure Actinium-225 Supply as Pipelines Expand”

BioSpace data show job postings live increased quarter over quarter, while layoffs fell year over year.

Original title: “2025 Q4 Job Market Report: Positive Signs Emerge for Job Seekers”

After the FDA’s decision to reject a review of Moderna’s mRNA-1010 flu shot, executives explain what Americans will miss out on as other nations embrace the technology.

Original title: “Moderna’s mRNA Tech Could Boost Flu Shot Efficacy. Americans Will Have To Wait”

Jim O'Neill was deputy secretary at the Department of Health and Human Services and also acting director of the CDC after the abrupt ouster of Susan Monarez in August 2025.

Original title: “CDC Left Leaderless Again After Acting Director Departs HHS”

Qureight has announced the appointment of Rebecca Simmons as COO

Original title: “Rebecca Simmons”

Through its AI Consortium and global forums, DIA is translating high‑level AI guidance into concrete workflows that match oversight to risk, from low‑stakes automation to decision‑critical regulatory analyses.

Original title: “How DIA Is Helping Regulators Turn AI Principles into Everyday Review Practice”

Premier life sciences consulting firm specializing in biotech M&A, pharmaceutical licensing, and cross-border partnerships. Track every major pharma M&A deal in 2025-2026. $228B+ in announced biotech deals, 17+ billion-dollar acquisitions, and the strategic forces driving the biggest dealmaking surge in pharma history. $228B+ in biotech deals. 17+ billion-dollar acquisitions. The definitive M&A tracker for pharma BD professionals. Industry analysts predict 2026 will see 20+ billion-dollar deals, potentially including the biggest biotech acquisition since Pfizer-Seagen. Merck is reportedly in advanced talks to acquire Revolution Medicines for up to $32 billion — which would make it the biggest biotech deal since Pfizer-Seagen.

Original title: “Pharma M&A Tracker 2026 | Every Major Acquisition & Deal Analysis | Vision Lifesciences”

Sales of Casgevy, a gene-edited treatment developed with CRISPR Therapeutics, more than tripled compared to the third quarter, a performance analysts saw as a bright spot in Vertex's report.

Original title: “Vertex’s CRISPR therapy rebounds in latest earnings”

Moderna will not commit to previous 2028 breakeven guidance as the ripple effects of the FDA’s refusal-to-file decision spread through its pipeline.

Original title: “Moderna’s FDA Challenges Stymie Breakeven Goal in ‘Fresh and Fluid’ Situation”

Following over a year of slow uptake, Vertex Pharmaceuticals and CRISPR Therapeutics expect Casgevy revenues to nearly triple in 2026, as patient access to the sickle cell disease and beta thalassemia gene therapy grows.

Original title: “Vertex, CRISPR Set Lofty Goal for Casgevy Gene Therapy as Patient Starts Ramp”

Lyell’s trial will test its experimental cancer cell therapy directly against marketed counterparts. Elsewhere, Biogen swapped board chairs and venture firms are joining up at a “pivotal time” for Europe.

Original title: “Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs”

Another FDA knockback for a gene therapy has investors and analysts redrawing expectations for the rare disease drug developer.

Original title: “Ultragenyx cuts jobs as it seeks path to profit in 2027”

The mRNA specialist reiterated its financial estimates for 2026 amid a challenging U.S. regulatory environment where its influenza vaccine just hit a major setback.

Original title: “Moderna shares jump as company affirms growth outlook”

The HHS secretary has four new senior advisors to help him “move faster and go further” on his Make America Healthy Again agenda.

Original title: “HHS elevates officials into Kennedy’s inner circle in advance of midterms”

Eli Lilly has long been gearing up for the launch of orforglipron, announcing as early as February 2024 that it was ramping up manufacturing investments for the weight-loss pill.

Original title: “Lilly Prepares $1B+ Orforglipron Stock Ahead of Approval as Novo Brings Wegovy Pill Overseas”

Analysts are keeping a close eye on Vertex’s kidney disease portfolio, anchored by the IgAN drug povetacicept, as its nonopioid painkiller Journavx is poised for “incremental” growth in the first half 2026, according to BMO Capital Markets.

Original title: “All Eyes on Vertex’s Kidney Franchise, as Painkiller Journavx Tops Half a Million Scripts”

Whisper it, but we may finally be seeing the IPO window reopening in 2026. Whisper it, but we may finally be seeing the IPO window reopening in 2026. | Whisper it, but we may finally be seeing the IPO window reopening in 2026. Beyond oncology, orphan diseases and the red-hot diabetes and obesity spaces are also in demand, Lane added. Flagship-founded antibody biotech Generate is latest to mull IPO That interest subsided to an annual average of closer to 20 listings by U.S. biotechs until 2025—when the number of IPOs sunk to a nadir of just 11, according to data from Pitchbook. But the mood music seems to have changed in the early weeks of 2026, with a steady stream of biopharmas lining up to ring the Nasdaq bell. Aktis Oncology set the tone in the early days of January, raking in $318 million via an upsized offering that the company will use to fund early-phase clinical trials of its two lead radiopharmaceutical candidates. While most of the initial crop of IPOs have come from U.S. companies, Belgium’s Agomab Therapeutics scored a respectable $200 million IPO on the Nasdaq. The immunology biotech’s pipeline centers on a pair of ALK5 inhibitors licensed from Spain’s Origo Biopharma. Last week’s public listing was needed to “really access deep and biotech-focused capital” to support this pipeline, Agomab CEO Tim Knotnerus told Fierce. “In order to have sufficient funding from long-term investors [and] a broader investor base to fund both of these studies, plus earlier research work, we felt it's the right time to access the public markets,” Knotnerus said in an interview.

Original title: “'When the markets opened, we were ready': Why biotech IPOs are back for 2026”

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patents and patent applications listed in the SUPPLEMENTARY INFORMATION section of this notice to Kyverna Therapeutics, Inc. ("Kyverna"), a company located in Emeryville, California, the United States of America.

Original title: “Prospective Grant of an Exclusive Patent License: In Vivo Manufactured Anti-CD19 Chimeric Antigen Receptor (CAR) Products for the Treatment or Prevention of B Cell Mediated Autoimmune Diseases”

Moderna’s mRNA-1010 was expected to contribute $1 billion to the company’s coffers by 2028. That plan is now out the window after the FDA refused to even look at the application.

Original title: “Flu Vaccine Rejection Imperils Moderna’s Breakeven Plans”

Even as Wall Street embraces blockchain technology, the process for going public remains much as it has for decades. Mike Belshe has worked in crypto since the industry’s early days, founding his firm BitGo back in 2013. He is a strong believer in the power of blockchain to transform finance, yet when the time came to take BitGo public this year, Belshe found the entire IPO process is built entirely around legacy practices. The current IPO process typically involves banks lining up wealthy investors to buy a company’s newly public stock at an agreed upon price in hopes of gaining a “pop” when the stock begins to trade among retail investors a short time later. “The technology can start to change how we take [companies] to market, and maybe more interestingly, it can break up just having the large incumbents that currently run the IPO processes to other more innovative types of markets that may be very different,” said Belshe. “The IPO process is actually pretty similarly unwieldy. It’s the same basic thing. You’re taking a token, or in this case, an equity, and you’re making it available on markets, and it starts out as a thin market.

Original title: “BitGo’s CEO just took his company public—and thinks the IPO process could be improved with blockchain | Fortune”